BiDil's impact [1] (multiple letters)

Nature Biotechnology

Volumn 23, Issue 11, 2005, Pages 1343-1344

  Puckrein, Gary ^a   Yancy, Clyde W ^b  

^a National Minority Health Month Foundation   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PACLITAXEL; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE CONTROL; DISEASE COURSE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; TREATMENT OUTCOME;

AFRICAN AMERICANS; DRUG APPROVAL; DRUG COMBINATIONS; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; RISK; UNITED STATES;

EID: 27944456885     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1105-1343b     Document Type: Letter

References (0)